Your session is about to expire
← Back to Search
123I-MIBG Scintigraphy for Cancer Detection
Phase 3
Waitlist Available
Led By Daniel Worsley, MD
Research Sponsored by Vancouver Coastal Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the presence, extent, or status of neuroendocrine tumors
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is studying if 123I-MIBG is a safe and effective diagnostic tool for neuroendocrine tumors.
Who is the study for?
This trial is for individuals with suspected or confirmed neuroendocrine tumors who need imaging to assess their condition. Participants should be able to follow the study's procedures but cannot have severe kidney issues, take certain medications, or be unable to lie flat. Pregnant or breastfeeding women may join only if benefits outweigh risks.Check my eligibility
What is being tested?
The trial is evaluating the safety and effectiveness of a diagnostic imaging agent called 123I-MIBG in patients with various types of neuroendocrine tumors such as Neuroblastoma and Thyroid Cancer.See study design
What are the potential side effects?
While not explicitly listed here, potential side effects may include reactions at the injection site, nausea, high blood pressure changes due to iodine content, and allergic reactions. Kidney function might also be affected.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I need a special scan to check for a type of tumor affecting my hormone-producing cells.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Vancouver Coastal HealthLead Sponsor
37 Previous Clinical Trials
711,912 Total Patients Enrolled
Daniel Worsley, MDPrincipal InvestigatorVancouver Coastal Health
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not pregnant or breastfeeding, or if I am, the benefits of the treatment outweigh the risks.I need a special scan to check for a type of tumor affecting my hormone-producing cells.I have kidney issues and can't stop taking certain medications.I cannot lie flat on my back comfortably.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 2 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What are the odds of serious side effects from this medication?
"3 is the team's estimation of this treatment's safety on a scale from 1 to 3. This is a Phase 3 trial, so while there is not extensive evidence, what data exists does support both efficacy and multiple rounds of safety."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger